彭雨晨, 冯新红, 张泳, 黄龙舰, 赵春阳, 王晓良, 王庆利, 彭英. 肌萎缩性侧索硬化症非临床药效学评价体系的探索J. 药学学报, 2019,54(5): 788-800. doi: 10.16438/j.0513-4870.2018-1141
引用本文: 彭雨晨, 冯新红, 张泳, 黄龙舰, 赵春阳, 王晓良, 王庆利, 彭英. 肌萎缩性侧索硬化症非临床药效学评价体系的探索J. 药学学报, 2019,54(5): 788-800. doi: 10.16438/j.0513-4870.2018-1141
PENG Yu-chen, FENG Xin-hong, ZHANG Yong, HUANG Long-jian, ZHAO Chun-yang, WANG Xiao-liang, WANG Qing-li, PENG Ying. Exploration of non-clinical pharmacodynamics evaluation system of amyotrophic lateral sclerosisJ. Acta Pharmaceutica Sinica, 2019,54(5): 788-800. doi: 10.16438/j.0513-4870.2018-1141
Citation: PENG Yu-chen, FENG Xin-hong, ZHANG Yong, HUANG Long-jian, ZHAO Chun-yang, WANG Xiao-liang, WANG Qing-li, PENG Ying. Exploration of non-clinical pharmacodynamics evaluation system of amyotrophic lateral sclerosisJ. Acta Pharmaceutica Sinica, 2019,54(5): 788-800. doi: 10.16438/j.0513-4870.2018-1141

肌萎缩性侧索硬化症非临床药效学评价体系的探索

Exploration of non-clinical pharmacodynamics evaluation system of amyotrophic lateral sclerosis

  • 摘要: 肌萎缩性侧索硬化(amyotrophic lateral sclerosis,ALS)是运动神经元病的最常见类型,其发病机制尚不明确。近年来,对于ALS遗传基础的研究进展促进了各种ALS疾病模型的出现和发展,为ALS相关药物及治疗方法的筛选提供了多种选择。本综述主要介绍肌萎缩性侧索硬化症的相关研究进展,对典型的非临床动物模型药物筛选评价体系进行归纳,包括转基因动物模型、基因敲除动物模型及自然发病动物模型,总结了规范化ALS非临床研究需要注意的问题,并对系统性规范化的非临床药效学研究方案提出建议。

     

    Abstract: Amyotrophic lateral sclerosis (ALS) is among the most common type of motor neuron diseases, and its pathogenesis remains unclear. In recent years, our understanding of the genetic basis of ALS has led to the development of various ALS disease models, which allow for screening of ALS-related drugs and treatment methods. This review focuses on the research progress of ALS, summarizes the systems of commonly used experi mental animal models, including transgenic animals, gene knockout approaches and autonomous animal models, points to the problems needing attention in standardized ALS non-clinical research, and proposes the criteria for selection of standardized R&D model.

     

/

返回文章
返回